FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2775468048> ?p ?o ?g. }

• W2775468048 endingPage "3308" @default.
• W2775468048 startingPage "3308" @default.
• W2775468048 abstract "Abstract Background The role of allogeneic stem cell transplantation in the management of myeloma remains uncertain as it is a procedure with significant mortality and low long term rates of disease control. We sought to evaluate the feasibility of using adjunctive Lenalidomide (Revlimid®) to augment long term myeloma response following Reduced-Intensity Conditioned (RIC) allograft in the UK NCRI trial LenaRIC (Lenalidomide in Reduced Intensity Conditioned Transplant)-ISRCTN:16228367. Material & Methods Forty (40) patients were recruited in this single arm phase II trial at ten UK stem cell transplant centres from June 2011-June 2015. All patients were in CR/VGPR 1 or 2 and had undergone a Melphalan conditioned autologous transplant in the previous 6 months. They then underwent a RIC allograft using Fludarabine & 2Gy TBI with ATG (Fresenius) as in vivo T-cell depletion (planned tandem SCT programme). Patients were scheduled to receive Lenalidomide (10mg until 2013, reduced to 5mg thereafter on DMEC advice) from day +35 if stable donor engraftment was present in the absence of GvHD. Lenalidomide was planned to be discontinued 12 months post-transplant with donor lymphocyte infusions given to patients with evidence of residual disease, relapse or mixed chimerism. Results Of the thirty nine(39) patients transplanted within 42 days of study entry, 8 were in CR1, 16 in VGPR1, 7 in CR2 and 8 in VGPR2. The median age was 49 years (range 35-65) with peripheral blood as the graft source in the 39 patients, from either sibling (n=16) or 10/10 matched unrelated donor (n=23). 1 patient failed to proceed to transplant. Of thirty four (34) evaluable patients, 28 (82.4%) achieved full donor T-cell chimerism and 32 (94.1%) full donor in whole blood. 34 patients completed at least one cycle of Lenalidomide. Mean number of cycles received was 7.4 (range 1-12, median 9.0). Mean dose was 5.2mg, median 5mg. 16 patients completed at least 10 cycles and 5 patients completed 12 cycles as per protocol treatment; of those completing >= 10 cycles, 5/16 received DLI. Safety data There were eight (8) patients who had biopsy-proven aGVHD (4 of grade 1-2 and 4 of grade 3- all 4 within 3 cycles of Lenalidomide) and 3 patients with cGVHD (2 extensive and 1 limited). No Grade 3/4 aGVHD was seen following DMEC advice to reduce the Lenalidomide dose to 5mg daily. 8 patients experienced grade 3 or 4 non-Haem toxicity. The majority of AEs were grade 1-2. Significant (Grade 3/4) non-Haem SAEs in this transplant population included Gastro-intestinal (4 patients), metabolism (4 patients), infection (13 patients) and vascular (4 patients). One year relapse-free survival was 84.3%. Clinical Outcomes Efficacy was assessed at a median follow-up of 445 days. The pre-transplant CR rate of 38.4% was improved to 67.6% at best response post-transplant. PFS at 2 years was 43.1% (figure 1a), OS at years 75.7% with a 2 year disease-free survival of 59.1% (figure 1b). Of the 10 patients who have died, 6 have been recorded as disease-related. Conclusions 1) Based on the pre-defined safety stopping rules, the LenaRIC study shows that post-graft Lenalidomide is safe and tolerated in a T-depleted RIC setting at a dose of 5mg daily- this results in a tolerable AE profile with an acceptable GVHD rate. 2) Acute GVHD only occurred in the first 3 cycles of exposure to Lenalidomide- consideration should be given to examining the longer term use of Lenalidomide beyond 12 months following a T-depleted RIC allograft to augment long term outcomes 3) CR rates were nearly doubled by this approach 4) Further work correlating Lenalidomide exposure with clinical events and immune reconstitution is ongoing. An unrestricted educational grant was provided to support the trial & adjunctive science by Cancer Research UK and by Celgene. Lenalidomide provided free of charge by Celgene. Lenograstim provided free of charge by Chugai. The support and time of participating patients and their families is gratefully acknowledged. Download : Download high-res image (77KB) Download : Download full-size image Disclosures Cook: Janssen: Honoraria, Other: Travel support, Research Funding; Amgen: Honoraria, Other: Travel support; Takeda: Honoraria; Myeloma UK: Membership on an entity's Board of Directors or advisory committees; Celgene: Honoraria, Other: Travel support, Research Funding; Jazz Pharmaceuticals: Honoraria. Brock: Merck: Other: travel expenses; Roche: Honoraria, Other: travel expenses; GlaxoSmithKline: Equity Ownership; Astra-Zeneca: Equity Ownership. Snowden: Sanofi: Honoraria. Hunter: Celgene: Other: Travel Support. Cavenagh: Takeda: Consultancy; Novartis: Consultancy; Janssen: Honoraria; Celgene: Consultancy. Cook: BMS: Consultancy, Honoraria; Sanofi: Consultancy, Honoraria, Speakers Bureau; Janssen: Consultancy, Honoraria, Research Funding, Speakers Bureau; Takeda: Consultancy, Honoraria, Research Funding, Speakers Bureau; Glycomimetics: Consultancy, Honoraria; Amgen: Consultancy, Honoraria, Speakers Bureau; Celgene: Consultancy, Honoraria, Research Funding, Speakers Bureau." @default.
• W2775468048 created "2017-12-22" @default.
• W2775468048 creator A5009006274 @default.
• W2775468048 creator A5019472985 @default.
• W2775468048 creator A5036384569 @default.
• W2775468048 creator A5037396617 @default.
• W2775468048 creator A5038099312 @default.
• W2775468048 creator A5038580329 @default.
• W2775468048 creator A5055600777 @default.
• W2775468048 creator A5060242205 @default.
• W2775468048 creator A5070847211 @default.
• W2775468048 creator A5072267975 @default.
• W2775468048 creator A5088636994 @default.
• W2775468048 date "2017-12-07" @default.
• W2775468048 modified "2023-09-28" @default.
• W2775468048 title "Reduced Intensity Stem Cell Transplantation Followed By Adjunctive Lenalidomide Is Tolerable and Safe and Improves Complete Response Rate in Multiple Myeloma:a UK NCRI Phase 2 Feasibility Study (LenaRIC)" @default.
• W2775468048 doi "https://doi.org/10.1182/blood.v130.suppl_1.3308.3308" @default.
• W2775468048 hasPublicationYear "2017" @default.
• W2775468048 type Work @default.
• W2775468048 sameAs 2775468048 @default.
• W2775468048 citedByCount "0" @default.
• W2775468048 crossrefType "journal-article" @default.
• W2775468048 hasAuthorship W2775468048A5009006274 @default.
• W2775468048 hasAuthorship W2775468048A5019472985 @default.
• W2775468048 hasAuthorship W2775468048A5036384569 @default.
• W2775468048 hasAuthorship W2775468048A5037396617 @default.
• W2775468048 hasAuthorship W2775468048A5038099312 @default.
• W2775468048 hasAuthorship W2775468048A5038580329 @default.
• W2775468048 hasAuthorship W2775468048A5055600777 @default.
• W2775468048 hasAuthorship W2775468048A5060242205 @default.
• W2775468048 hasAuthorship W2775468048A5070847211 @default.
• W2775468048 hasAuthorship W2775468048A5072267975 @default.
• W2775468048 hasAuthorship W2775468048A5088636994 @default.
• W2775468048 hasConcept C126322002 @default.
• W2775468048 hasConcept C141071460 @default.
• W2775468048 hasConcept C2776063141 @default.
• W2775468048 hasConcept C2776364478 @default.
• W2775468048 hasConcept C2776694085 @default.
• W2775468048 hasConcept C2776755627 @default.
• W2775468048 hasConcept C2778684742 @default.
• W2775468048 hasConcept C2779263901 @default.
• W2775468048 hasConcept C2911091166 @default.
• W2775468048 hasConcept C71924100 @default.
• W2775468048 hasConceptScore W2775468048C126322002 @default.
• W2775468048 hasConceptScore W2775468048C141071460 @default.
• W2775468048 hasConceptScore W2775468048C2776063141 @default.
• W2775468048 hasConceptScore W2775468048C2776364478 @default.
• W2775468048 hasConceptScore W2775468048C2776694085 @default.
• W2775468048 hasConceptScore W2775468048C2776755627 @default.
• W2775468048 hasConceptScore W2775468048C2778684742 @default.
• W2775468048 hasConceptScore W2775468048C2779263901 @default.
• W2775468048 hasConceptScore W2775468048C2911091166 @default.
• W2775468048 hasConceptScore W2775468048C71924100 @default.
• W2775468048 hasLocation W27754680481 @default.
• W2775468048 hasOpenAccess W2775468048 @default.
• W2775468048 hasPrimaryLocation W27754680481 @default.
• W2775468048 hasRelatedWork W19039903 @default.
• W2775468048 hasRelatedWork W193198815 @default.
• W2775468048 hasRelatedWork W2468483596 @default.
• W2775468048 hasRelatedWork W2536796599 @default.
• W2775468048 hasRelatedWork W2546435969 @default.
• W2775468048 hasRelatedWork W2578546045 @default.
• W2775468048 hasRelatedWork W2590597646 @default.
• W2775468048 hasRelatedWork W2595988118 @default.
• W2775468048 hasRelatedWork W2596690970 @default.
• W2775468048 hasRelatedWork W2600140196 @default.
• W2775468048 hasRelatedWork W2735715421 @default.
• W2775468048 hasRelatedWork W2759274067 @default.
• W2775468048 hasRelatedWork W2913403574 @default.
• W2775468048 hasRelatedWork W2962628474 @default.
• W2775468048 hasRelatedWork W2979663436 @default.
• W2775468048 hasRelatedWork W2979797128 @default.
• W2775468048 hasRelatedWork W2980027503 @default.
• W2775468048 hasRelatedWork W3015486851 @default.
• W2775468048 hasRelatedWork W3041001077 @default.
• W2775468048 hasRelatedWork W3041305219 @default.
• W2775468048 hasVolume "130" @default.
• W2775468048 isParatext "false" @default.
• W2775468048 isRetracted "false" @default.
• W2775468048 magId "2775468048" @default.
• W2775468048 workType "article" @default.